Today
July 25, 2026Dilution Risk
0Last 7DListing Risk
37Last 30DEarnings
8Last 7DInsider / Ownership
3Last 14DDividends
1Last 30DFDA / Clinical
13Last 30DAbercrombie & Fitch reported record Q1 net sales ($1.1B) and EPS of $1.47 that exceeded its outlook, maintained FY guidance and signaled sizable share repurchases — indicating continued operational momentum despite regional softness in EMEA.
BioLineRx reported Q1 2026 results and attached interim financials and an operating review that include a going-concern disclosure (accumulated losses of $403M). Company progress on GLIX1 (first patient dosed) is a positive development, but the going-concern and ongoing cash burn raise near-term financial risk.
TDAC announced a Business Combination Agreement to merge with ProLogium (dated May 27, 2026). The filing includes the merger agreement and related voting/lock‑up/registration exhibits, an implied equity value (~$3.8B), warrant terms ($11.50 exercise), and Available Cash and closing/deadline mechanics — a de‑SPAC transaction that will require shareholder approvals and affects listing, dilution and timing.
Vote is pending; 3 proposals need result and post-meeting implementation checks.
The board declared a routine quarterly dividend with record and payment dates disclosed.
The IPO range is set, with SEC effectiveness and final pricing still ahead.
Vote approved, but redemptions leave minimum cash and liquidity as the main closing variables.
Registers 4.5M shares at $0.0225; auditor cites going‑concern.
Algorhythm registered 10,000,000 resale shares while auditors cite substantial doubt about going concern.
Company registered 22.6M shares for resale; auditor issued going-concern opinion.
F-3 conversion registers large resale and warrant share overhang that may pressure BDMD shares.
Registers $270M shelf for potential future securities issuances.
SunPower registered 48.5M shares for resale under an equity line, enabling potential dilution.
SunPower registered 22.38M shares for resale by Yorkville under a SEPA.
Registers large selling shareholder block and warrant exercise overhang.
Collab Z amended its S-1 to register 5,000,000 common shares for an IPO.
Quantinuum filed an S-1/A to offer 21.05M Class A shares at $45–$50, planning Nasdaq listing QNT.
Applied Aerospace filed an S‑1/A for a 32.5M‑share IPO, range $18–$21, to list as AADX.
INNIO files S-1/A for 75M-share resale IPO at $24–$27, seeking Nasdaq listing under INIO.
S-1/A registers 6.925M Class A shares at $25–$27; NYSE listing planned.